"Apolipoproteins B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Major structural proteins of triacylglycerol-rich LIPOPROTEINS. There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. ApoB-100 expressed in the liver is found in low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). ApoB-48 expressed in the intestine is found in CHYLOMICRONS. They are important in the biosynthesis, transport, and metabolism of triacylglycerol-rich lipoproteins. Plasma Apo-B levels are high in atherosclerotic patients but non-detectable in ABETALIPOPROTEINEMIA.
| Descriptor ID |
D001055
|
| MeSH Number(s) |
D10.532.091.300 D12.776.070.400.300 D12.776.521.120.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Apolipoproteins B".
Below are MeSH descriptors whose meaning is more specific than "Apolipoproteins B".
This graph shows the total number of publications written about "Apolipoproteins B" by people in this website by year, and whether "Apolipoproteins B" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 3 | 1 | 4 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 3 | 4 |
| 2001 | 2 | 4 | 6 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 0 | 1 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 1 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 1 | 4 |
| 2011 | 1 | 3 | 4 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 4 | 6 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 1 | 3 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoproteins B" by people in Profiles.
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026 Feb 05; 394(6):529-539.
-
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 01 13; 335(2):129-139.
-
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025 Nov 21; 46(44):4737-4750.
-
Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland - the Jurasz Lipid Study (JLS). Lipids Health Dis. 2025 Sep 29; 24(1):300.
-
High LDL Particle and APOB Concentrations in Patients With Adrenal Cortical Adenomas. J Clin Endocrinol Metab. 2024 Dec 18; 110(1):195-207.
-
Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct; 18(5):e647-e663.
-
Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels. JAMA Cardiol. 2024 Aug 01; 9(8):741-747.
-
High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner. Atherosclerosis. 2023 11; 384:117150.
-
Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease. JAMA Cardiol. 2023 03 01; 8(3):258-267.